Our consultancy provides strategic direction and tactical execution for development of novel pharmaceuticals and medical devices
Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
Gary Novack, Ph.D.
Gary D. Novack, Ph.D., President of PharmaLogic Development, Inc. has decades of experience in successful product development. Together with his team of senior experts, PharmaLogic can help you execute that plan.
In our 25+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
If you don’t know where you are going, any road will get you there.
– Lewis Carroll
Tom Gadek, Ph.D. gives two video talks, captured by UCSF's "iBiology" series. The first talk focuses on the creation of SARCode, later acquired by Shire The second talk focuses on the science of lifitegrast, now known as Xiidra(R). Our role in the early development...read more
At Glaucoma Research Foundation's New Horizons Forum in San Francisco. Dr. Richard Lewis and Dr. Novack moderated a session with Dr. Wiley Chambers (CDER) and Dr. Tieuvi Nguyen (CDRH) in discussion of current ophthalmic issues at FDA....read more
in 2016, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommended 81 medicines for marketing authorization. Of these 27 were "new active substances" and 17 had an orphan designation. There were 2 negative opinions, which later...read more